Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
17. Dezember 2024 07:00 ET
|
Immunocore Holdings plc
The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care, in patients with advanced cancers expressing PIWIL1 First...
Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc.
03. Dezember 2024 05:00 ET
|
Medigene AG
Payment triggered by development milestone achieved by Regeneron’s collaborator in China, JW TherapeuticsProgresses first clinical use of Medigene’s End-to-End Platform to generate potentially...
Medigene AG reports Financial Results and Business Update for Q3 2024
24. Oktober 2024 01:30 ET
|
Medigene AG
Planegg/Martinsried, October 24, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Immunocore to present at the 2024 Cantor Global Healthcare Conference
12. September 2024 16:05 ET
|
Immunocore Holdings plc
Immunocore to present at the 2024 Cantor Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 12 September 2024) Immunocore Holdings plc (Nasdaq:...
Medigene Reports Results of Annual General Meeting
24. Juni 2024 11:05 ET
|
Medigene AG
Shareholders approve all proposed resolutionsRe-election of two members of the Supervisory BoardReduction of share capital by consolidation of shares at a ratio of 2:1 approvedCreation of new...
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
18. Juni 2024 07:00 ET
|
Immunocore Holdings plc
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma ...
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
01. Juni 2024 08:00 ET
|
Immunocore Holdings plc
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were...
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
31. Mai 2024 16:05 ET
|
Immunocore Holdings plc
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 Monotherapy...
Immunocore to present at the Jefferies Global Healthcare Conference
30. Mai 2024 16:00 ET
|
Immunocore Holdings plc
Immunocore to present at the Jefferies Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 30 May 2024) Immunocore Holdings plc (Nasdaq: IMCR)...
TCR UK and Woya Digital Renew Marketing Partnership for 2024
10. Mai 2024 12:32 ET
|
TCR UK
Birmingham, UK, May 10, 2024 (GLOBE NEWSWIRE) -- TCR UK and Woya Digital Renew Marketing Partnership for 2024 TCR UK is thrilled to announce the renewal of its marketing partnership with Woya...